Crinetics Pharmaceuticals CRNX Business Segments — Early Research and Development Programs

Similar metrics at other companies

RCUSReportable segment — Early-stage development and preclinical programs

$18M-57.1%

TVTXReportable Segment — R&D

$57.09M+21.8%

TVTXReportable Segment — External research and development

$27.73M+24.0%

TARSReportable Segment — R&D

$22.35M+55.1%

VCYTReportable Segment — R&D

$27.1M+52.9%

INDVReportable Segment — R&D

$16M-27.3%

Other financials

Income statement

See full

Revenue$10.7M+2,873%

Gross profit$10.5M+2,818%

Operating income-$140.4M-26.0%

Net income-$127.8M-32.1%

EPS (diluted)-$1.23-18.3%

Balance sheet

See full

Cash & equivalents$115.1M+20.1%

Total debt$47.9M-5.8%

Total equity$1.3B+2.1%

Total assets$1.4B+2.9%

Cash flow

See full

Operating cash flow-$124.7M-41.0%

CapEx$820.0K-33.8%

Free cash flow-$125.5M-40.0%

Valuation

See full

Market cap$3.79B+21.9%

Profitability

See full

Gross margin150%-15.6pp

Operating margin-3,020.3%-1,463pp

Net margin-2,747.2%-1,328pp

FCF margin-2,321.7%-1,122pp

Returns & leverage

See full

Return on equity-39.2%+14.5pp

Debt / equity0×0.0×

Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept crnx:EarlyResearchAndDevelopmentPrograms.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's business segments — early research and development programs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Crinetics Pharmaceuticals's business segments — early research and development programs?: Crinetics Pharmaceuticals (CRNX) reported business segments — early research and development programs of $9.67M in Q1 2026.
What does business segments — early research and development programs mean?: This metric aggregates the costs associated with the company's discovery-stage and early-pipeline research initiatives. It represents the investment in future growth drivers that have not yet reached advanced clinical development. This figure highlights the company's commitment to long-term innovation and pipeline replenishment.